These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6224732)

  • 1. Some proteins not belonging to the clotting or to the kallikrein-kinin system altered by kallikrein.
    Péjaudier L; Kichenin V; Audran R; Steinbuch M
    Hoppe Seylers Z Physiol Chem; 1983 Jun; 364(6):651-4. PubMed ID: 6224732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of proteases in coagulation, kinin-forming and complement systems by alpha2-plasmin inhibitor.
    Moroi M; Aoki N
    J Biochem; 1977 Oct; 82(4):969-72. PubMed ID: 144728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
    Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
    J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the interaction between collagen and a plasma kallikrein-like activity. Evidence for a surface-active enzyme system.
    Harpel PC
    J Clin Invest; 1972 Jul; 51(7):1813-22. PubMed ID: 4338122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation.
    Eisen V; Loveday C
    Br J Pharmacol; 1973 Dec; 49(4):678-87. PubMed ID: 4788038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema.
    Nielsen EW; Johansen HT; Høgåsen K; Wuillemin W; Hack CE; Mollnes TE
    Scand J Immunol; 1996 Aug; 44(2):185-92. PubMed ID: 8711433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome.
    Brus F; van Oeveren W; Okken A; Oetomo SB
    Pediatr Res; 1994 Nov; 36(5):647-53. PubMed ID: 7877886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [General mechanisms of biochemical regulation of the kallikrein, clotting and fibrinolytic systems of the blood].
    Gomazkov OA; Komissarova NV
    Usp Sovrem Biol; 1976; 82(6):356-70. PubMed ID: 65846
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative evaluation of the kallikrein-kinin, plasmin and thrombin blood systems in hypertension].
    Karpitskiĭ VV
    Kardiologiia; 1983 Apr; 23(4):98-100. PubMed ID: 6223170
    [No Abstract]   [Full Text] [Related]  

  • 10. The intrinsic coagulation-kinin pathway, complement cascades, plasma renin-angiotensin system, and their interrelationships.
    Kaplan AP; Ghebrehiwet B; Silverberg M; Sealey JE
    Crit Rev Immunol; 1981 Sep; 3(1):75-93. PubMed ID: 7047077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.
    Patston PA; Roodi N; Schifferli JA; Bischoff R; Courtney M; Schapira M
    J Biol Chem; 1990 Jun; 265(18):10786-91. PubMed ID: 2191958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.
    Schreiber AD; Kaplan AP; Austen KF
    J Clin Invest; 1973 Jun; 52(6):1402-9. PubMed ID: 4703226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Potentiation of kinin activity by products of proteolytic protein degradation].
    Czokalo M; Buluk K; Zuch A; Lukjan H; Tymińska-Brzósko R
    Pol Tyg Lek; 1974 Nov; 29(46):1965-8. PubMed ID: 4279398
    [No Abstract]   [Full Text] [Related]  

  • 14. High molecular weight kininogen: its inability to correct the clotting of kininogen-deficient plasma after cleavage of bradykinin by plasma kallikrein, plasmin or trypsin.
    Chan JY; Movat HZ; Burrowes CE
    Thromb Res; 1979; 14(6):817-24. PubMed ID: 157559
    [No Abstract]   [Full Text] [Related]  

  • 15. Surface-mediated reactions in the formation of thrombin, plasmin and kallikrein.
    Ogston D; Bennett B
    Br Med Bull; 1978 May; 34(2):107-12. PubMed ID: 148934
    [No Abstract]   [Full Text] [Related]  

  • 16. Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency.
    Smith MA; Kerr MA
    Immunology; 1985 Nov; 56(3):561-70. PubMed ID: 2934317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys.
    Bork K; Kleist R; Hardt J; Witzke G
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):325-32. PubMed ID: 19474702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorogenic peptide substrates for proteases in blood coagulation, kallikrein-kinin and fibrinolysis systems.
    Iwanaga S; Morita T; Kato H; Harada T; Adachi N; Sugo T; Maruyama I; Takada K; Kimura T; Sakakibara S
    Adv Exp Med Biol; 1979; 120A():147-63. PubMed ID: 158955
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydrolysis of plasma kallikrein by trypsin and plasmin and the formation of active fragments.
    Sampaio CA; Vidmar S; Hamaguchi A; Sampaio MU
    Adv Exp Med Biol; 1986; 198 Pt B():105-11. PubMed ID: 2949543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human inter-alpha-trypsin inhibitor. Limited proteolysis by trypsin, plasmin, kallikrein and granulocytic elastase and inhibitory properties of the cleavage products.
    Dietl T; Dobrinski W; Hochstrasser K
    Hoppe Seylers Z Physiol Chem; 1979 Sep; 360(9):1313-8. PubMed ID: 92450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.